Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001401914-25-000022
Filing Date
2025-05-13
Accepted
2025-05-13 16:04:11
Documents
68
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q dare-20250331.htm   iXBRL 10-Q 936477
2 EX-10.1 ex101_noneedircomp.htm EX-10.1 34164
3 EX-31.1 exhibit311_20250331.htm EX-31.1 15305
4 EX-32.1 exhibit321_20250331.htm EX-32.1 4273
10 dare-20250331_g1.jpg GRAPHIC 130914
  Complete submission text file 0001401914-25-000022.txt   6735982

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dare-20250331.xsd EX-101.SCH 70316
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dare-20250331_cal.xml EX-101.CAL 66349
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dare-20250331_def.xml EX-101.DEF 261282
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dare-20250331_lab.xml EX-101.LAB 726333
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dare-20250331_pre.xml EX-101.PRE 471538
71 EXTRACTED XBRL INSTANCE DOCUMENT dare-20250331_htm.xml XML 700142
Mailing Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122
Business Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122 858-926-7655
Dare Bioscience, Inc. (Filer) CIK: 0001401914 (see all company filings)

EIN.: 204139823 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36395 | Film No.: 25939901
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)